Oxigene <360p 2026>

Lead candidate; received and Orphan Drug designations for platinum-resistant ovarian cancer. OXi4503

OXiGENE’s primary development programs were based on , natural products originally derived from the African bush willow tree. Drug Candidate Indication Current Status/Highlights CA4P (Fosbretabulin) Ovarian Cancer, Glioblastoma, Anaplastic Thyroid Cancer Oxigene

In 2010, OXiGENE acquired VaxGen, Inc. in a stock-for-stock merger to bolster its cash reserves by approximately $33 million. Lead candidate; received and Orphan Drug designations for

The shift to Mateon Therapeutics reflected a broader focus on "Vascular Targeted Therapy" (VTT), which combines VDAs with anti-angiogenic agents to trap and destroy tumor cores while preventing new vessel growth. Historical Acquisitions: in a stock-for-stock merger to bolster its cash

A second-generation VDA focused on hematologic malignancies; initiated Phase 1b/2 trials in 2015. Myopic Macular Degeneration

Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)

Investigated as a topical or systemic treatment to prevent abnormal blood vessel leakage in the eye.